HF
LRMR icon

HRT Financial’s Larimar Therapeutics LRMR Stock Holding History

HRT Financial’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-121,885
Closed -$548K – 4865
2026
Q1 		$548K Buy
+121,885
New +$487K ﹤0.01% 2448
2024
Q4 		– Sell
-178,413
Closed -$1.17M – 2892
2024
Q3 		$1.17M Buy
+178,413
New +$1.43M 0.01% 1160
2023
Q2 		– Sell
-78,157
Closed -$354K – 2914
2023
Q1 		$354K Buy
+78,157
New +$408K ﹤0.01% 1613
2021
Q4 		– Sell
-21,174
Closed -$244K – 3684
2021
Q3 		$244K Buy
+21,174
New +$254K ﹤0.01% 2550
2021
Q2 		– Sell
-28,340
Closed -$414K – 3231
2021
Q1 		$414K Buy
+28,340
New +$515K ﹤0.01% 1928
2020
Q1 		– Sell
-3,100
Closed -$41K – 1108
2019
Q4 		$41K Buy
3,100
+2,108
+213% +$20.1K ﹤0.01% 1074
2019
Q3 		$8K Buy
+992
New +$10.9K ﹤0.01% 1357

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

HRT Financial's LRMR Position: Q2 2026 in Review

HRT Financial sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 121,885 shares — an estimated $548K sold.

HRT Financial first reported a position in LRMR in Q3 2019 and held it in 7 quarters. The position peaked at $1.17M in Q3 2024. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • HRT Financial reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 121,885 Larimar Therapeutics shares in Q2 2026, an estimated $548K.
  • HRT Financial first reported a position in Larimar Therapeutics in Q3 2019 and held it in 7 quarters.
  • HRT Financial's Larimar Therapeutics position peaked at $1.17M in Q3 2024.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.